Curated News
By: NewsRamp Editorial Staff
March 06, 2026

LIXTE Acquires Liora, Boosting Proton Therapy for Cancer Treatment

Discuss on LinkedIn Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • LIXTE's acquisition of Liora Technologies gives it a competitive edge in cancer treatment with the cost-effective LiGHT proton therapy system, potentially expanding market share.
  • The LiGHT System uses a proton beam to deliver high dose rates to deep tumors, reducing installation costs and treatment sessions compared to current technologies.
  • This acquisition advances cancer therapy by making proton treatment more accessible and efficient, improving patient outcomes and increasing the number of people served.
  • LIXTE's new LiGHT System, developed from CERN technology, offers a novel approach to proton therapy that could revolutionize how tumors are treated.

Impact - Why it Matters

This acquisition matters because it could significantly improve cancer treatment outcomes and accessibility. Proton therapy is a precise form of radiation therapy that targets tumors while minimizing damage to surrounding healthy tissues, but it has been limited by high costs and complex infrastructure. The LiGHT System's potential to reduce installation costs and treatment sessions could make this advanced therapy more widely available, benefiting patients with hard-to-treat cancers. For investors, it represents LIXTE's strategic growth in oncology, combining drug development with innovative technology to address unmet medical needs. In the broader context, such advancements are crucial as cancer remains a leading cause of death globally, and innovations like this could enhance survival rates and quality of life for millions affected by the disease.

Summary

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, has strategically acquired Liora Technologies, a pioneer in advanced proton therapy systems for cancer treatment. This acquisition brings Liora's flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), under LIXTE's umbrella as a wholly owned subsidiary. The LiGHT System represents a significant advancement in proton therapy, offering advantages over existing technologies by delivering very high dose rates to deep-seated tumors with unique biological effects, as highlighted by Professor Steve Myers, former Director of Accelerators and Technology at CERN. This innovative system is expected to reduce installation costs, decrease the number of treatment sessions required, and increase patient capacity at treatment centers, potentially revolutionizing cancer care accessibility.

LIXTE's core focus remains on cancer drug development, with its first-in-class lead clinical PP2A inhibitor, LB-100, showing promise in enhancing chemotherapies and immunotherapies. The company is advancing a new treatment paradigm called "activation lethality," supported by a comprehensive patent portfolio, with proof-of-concept clinical trials underway for conditions like ovarian clear cell carcinoma and metastatic colon cancer. This news was reported by TinyGems, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides extensive distribution services for innovative small-cap and mid-cap companies. For more details, readers can visit the full article via the provided link.

The acquisition underscores LIXTE's commitment to expanding its oncology portfolio by integrating cutting-edge therapeutic technologies. By combining Liora's proton therapy expertise with its own drug development pipeline, LIXTE aims to offer more comprehensive and effective cancer treatments. This move could accelerate the availability of advanced therapies, benefiting patients through improved outcomes and reduced treatment burdens. The collaboration highlights the growing trend of biotech companies leveraging acquisitions to enhance their capabilities and drive innovation in the fight against cancer, as detailed in the original content from TinyGems.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, LIXTE Acquires Liora, Boosting Proton Therapy for Cancer Treatment

blockchain registration record for this content.